CRL Charles River Laboratories International, Inc.

Price (delayed)

$224.68

Market cap

$11.18B

P/E Ratio

36.83

Dividend/share

N/A

EPS

$6.1

Enterprise value

$13.1B

Sector: Healthcare
Industry: Diagnostics & Research
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client’s use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Highlights

The net income has increased by 30% year-on-year and by 11% since the previous quarter
The EPS rose by 28% YoY and by 11% QoQ
The quick ratio has declined by 19% since the previous quarter but it is up by 3% year-on-year
Charles River Laboratories International's debt has decreased by 10% QoQ but it has increased by 6% YoY
The price to earnings (P/E) is 22% higher than the last 4 quarters average of 30.2 and 22% higher than the 5-year quarterly average of 30.3

Key stats

What are the main financial stats of CRL
Market
Shares outstanding
49.74M
Market cap
$11.18B
Enterprise value
$13.1B
Valuations
Price to earnings (P/E)
36.83
Price to book (P/B)
5.88
Price to sales (P/S)
3.95
EV/EBIT
28.61
EV/EBITDA
19.16
EV/Sales
4.64
Earnings
Revenue
$2.82B
EBIT
$457.73M
EBITDA
$683.61M
Free cash flow
$446.33M
Per share
EPS
$6.1
Free cash flow per share
$8.98
Book value per share
$38.18
Revenue per share
$56.82
TBVPS
$52.97
Balance sheet
Total assets
$5.21B
Total liabilities
$3.29B
Debt
$2.16B
Equity
$1.9B
Working capital
$353.26M
Liquidity
Debt to equity
1.14
Current ratio
1.45
Quick ratio
1.04
Net debt/EBITDA
2.81
Margins
EBITDA margin
24.2%
Gross margin
36.7%
Net margin
10.7%
Operating margin
14.6%
Efficiency
Return on assets
5.9%
Return on equity
17.4%
Return on invested capital
11.9%
Return on capital employed
10.3%
Return on sales
16.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRL stock price

How has the Charles River Laboratories International stock price performed over time
Intraday
-3.16%
1 week
-4.79%
1 month
-3.49%
1 year
59.61%
YTD
47.08%
QTD
-0.78%

Financial performance

How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$2.82B
Gross profit
$1.04B
Operating income
$412.59M
Net income
$301.46M
Gross margin
36.7%
Net margin
10.7%
The net income has increased by 30% year-on-year and by 11% since the previous quarter
CRL's operating income is up by 20% YoY and by 11% QoQ
Charles River Laboratories International's net margin has increased by 18% YoY and by 8% QoQ
Charles River Laboratories International's gross profit has increased by 12% YoY and by 4.3% QoQ

Growth

What is Charles River Laboratories International's growth rate over time

Valuation

What is Charles River Laboratories International stock price valuation
P/E
36.83
P/B
5.88
P/S
3.95
EV/EBIT
28.61
EV/EBITDA
19.16
EV/Sales
4.64
The EPS rose by 28% YoY and by 11% QoQ
The price to earnings (P/E) is 22% higher than the last 4 quarters average of 30.2 and 22% higher than the 5-year quarterly average of 30.3
The price to book (P/B) is 25% higher than the 5-year quarterly average of 4.7 and 25% higher than the last 4 quarters average of 4.7
The equity is up by 24% year-on-year and by 8% since the previous quarter
The P/S is 46% higher than the 5-year quarterly average of 2.7 and 32% higher than the last 4 quarters average of 3.0
CRL's revenue is up by 12% year-on-year and by 2.7% since the previous quarter

Efficiency

How efficient is Charles River Laboratories International business performance
The ROS rose by 27% YoY and by 17% QoQ
The company's return on invested capital rose by 21% YoY and by 18% QoQ
The company's return on assets rose by 9% YoY and by 7% QoQ
The ROE has grown by 7% YoY and by 5% from the previous quarter

Dividends

What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRL.

Financial health

How did Charles River Laboratories International financials performed over time
The company's total assets is 59% higher than its total liabilities
The quick ratio has declined by 19% since the previous quarter but it is up by 3% year-on-year
The total liabilities rose by 9% YoY but it fell by 5% QoQ
Charles River Laboratories International's debt is 14% higher than its equity
The equity is up by 24% year-on-year and by 8% since the previous quarter
Charles River Laboratories International's debt to equity has decreased by 17% from the previous quarter and by 14% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.